Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 2.40
BSPM's Cash to Debt is ranked higher than
75% of the 907 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.47 vs. BSPM: 2.40 )
BSPM' s 10-Year Cash to Debt Range
Min: 1.14   Max: No Debt
Current: 2.4

Equity to Asset 0.88
BSPM's Equity to Asset is ranked higher than
93% of the 823 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. BSPM: 0.88 )
BSPM' s 10-Year Equity to Asset Range
Min: 0.79   Max: 0.96
Current: 0.88

0.79
0.96
Interest Coverage 1.38
BSPM's Interest Coverage is ranked lower than
52% of the 548 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 124.75 vs. BSPM: 1.38 )
BSPM' s 10-Year Interest Coverage Range
Min: 1.38   Max: 9999.99
Current: 1.38

1.38
9999.99
F-Score: 4
Z-Score: 3.03
M-Score: -0.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -0.51
BSPM's Operating margin (%) is ranked higher than
60% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.41 vs. BSPM: -0.51 )
BSPM' s 10-Year Operating margin (%) Range
Min: -44.17   Max: 30.5
Current: -0.51

-44.17
30.5
Net-margin (%) 4.80
BSPM's Net-margin (%) is ranked higher than
71% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.06 vs. BSPM: 4.80 )
BSPM' s 10-Year Net-margin (%) Range
Min: -40.55   Max: 24.95
Current: 4.8

-40.55
24.95
ROE (%) 4.26
BSPM's ROE (%) is ranked higher than
69% of the 879 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. BSPM: 4.26 )
BSPM' s 10-Year ROE (%) Range
Min: -29.81   Max: 34.28
Current: 4.26

-29.81
34.28
ROA (%) 3.78
BSPM's ROA (%) is ranked higher than
74% of the 911 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.14 vs. BSPM: 3.78 )
BSPM' s 10-Year ROA (%) Range
Min: -26.05   Max: 30.2
Current: 3.78

-26.05
30.2
ROC (Joel Greenblatt) (%) -0.82
BSPM's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 905 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.06 vs. BSPM: -0.82 )
BSPM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -54.03   Max: 102.48
Current: -0.82

-54.03
102.48
Revenue Growth (3Y)(%) -23.60
BSPM's Revenue Growth (3Y)(%) is ranked higher than
53% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. BSPM: -23.60 )
BSPM' s 10-Year Revenue Growth (3Y)(%) Range
Min: -23.6   Max: 56.6
Current: -23.6

-23.6
56.6
EBITDA Growth (3Y)(%) -45.50
BSPM's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.30 vs. BSPM: -45.50 )
BSPM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -45.5   Max: 50.3
Current: -45.5

-45.5
50.3
EPS Growth (3Y)(%) -68.40
BSPM's EPS Growth (3Y)(%) is ranked higher than
50% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. BSPM: -68.40 )
BSPM' s 10-Year EPS Growth (3Y)(%) Range
Min: -68.4   Max: 49.4
Current: -68.4

-68.4
49.4
» BSPM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

BSPM Guru Trades in Q4 2013

Jim Simons 320,142 sh (+63.03%)
» More
Q1 2014

BSPM Guru Trades in Q1 2014

Jim Simons 541,070 sh (+69.01%)
» More
Q2 2014

BSPM Guru Trades in Q2 2014

Jim Simons 563,670 sh (+4.18%)
» More
Q3 2014

BSPM Guru Trades in Q3 2014

Jim Simons 594,670 sh (+5.5%)
» More
» Details

Insider Trades

Latest Guru Trades with BSPM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 6.20
BSPM's P/E(ttm) is ranked higher than
99% of the 950 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.90 vs. BSPM: 6.20 )
BSPM' s 10-Year P/E(ttm) Range
Min: 1.03   Max: 156.32
Current: 6.2

1.03
156.32
P/B 0.25
BSPM's P/B is ranked higher than
99% of the 950 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.43 vs. BSPM: 0.25 )
BSPM' s 10-Year P/B Range
Min: 0.11   Max: 3.04
Current: 0.25

0.11
3.04
P/S 0.29
BSPM's P/S is ranked higher than
99% of the 950 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.93 vs. BSPM: 0.29 )
BSPM' s 10-Year P/S Range
Min: 0.13   Max: 2.2
Current: 0.29

0.13
2.2
EV-to-EBIT -42.38
BSPM's EV-to-EBIT is ranked higher than
60% of the 950 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.99 vs. BSPM: -42.38 )
BSPM' s 10-Year EV-to-EBIT Range
Min: -77.1   Max: 97.5
Current: -42.38

-77.1
97.5
Shiller P/E 2.47
BSPM's Shiller P/E is ranked higher than
99% of the 950 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 146.99 vs. BSPM: 2.47 )
BSPM' s 10-Year Shiller P/E Range
Min: 1.15   Max: 6.19
Current: 2.47

1.15
6.19
Current Ratio 5.51
BSPM's Current Ratio is ranked higher than
87% of the 890 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.42 vs. BSPM: 5.51 )
BSPM' s 10-Year Current Ratio Range
Min: 1.68   Max: 19.49
Current: 5.51

1.68
19.49
Quick Ratio 5.43
BSPM's Quick Ratio is ranked higher than
89% of the 889 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. BSPM: 5.43 )
BSPM' s 10-Year Quick Ratio Range
Min: 1.63   Max: 19.17
Current: 5.43

1.63
19.17

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 0.83
BSPM's Price/Net Current Asset Value is ranked higher than
99% of the 950 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. BSPM: 0.83 )
BSPM' s 10-Year Price/Net Current Asset Value Range
Min: 0.37   Max: 5.93
Current: 0.83

0.37
5.93
Price/Tangible Book 0.32
BSPM's Price/Tangible Book is ranked higher than
99% of the 950 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.13 vs. BSPM: 0.32 )
BSPM' s 10-Year Price/Tangible Book Range
Min: 0.19   Max: 3.49
Current: 0.32

0.19
3.49
Price/DCF (Projected) 0.22
BSPM's Price/DCF (Projected) is ranked higher than
99% of the 950 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.84 vs. BSPM: 0.22 )
BSPM' s 10-Year Price/DCF (Projected) Range
Min: 0.1   Max: 0.59
Current: 0.22

0.1
0.59
Price/Median PS Value 0.82
BSPM's Price/Median PS Value is ranked higher than
90% of the 950 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.27 vs. BSPM: 0.82 )
BSPM' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 5.8
Current: 0.82

0.39
5.8
Price/Graham Number 0.30
BSPM's Price/Graham Number is ranked higher than
99% of the 950 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.46 vs. BSPM: 0.30 )
BSPM' s 10-Year Price/Graham Number Range
Min: 0.12   Max: 1.24
Current: 0.3

0.12
1.24
Earnings Yield (Greenblatt) -2.40
BSPM's Earnings Yield (Greenblatt) is ranked higher than
59% of the 905 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. BSPM: -2.40 )
BSPM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 7626.1
Current: -2.4

1
7626.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:7BNA.Germany,
Biostar Pharmaceuticals Inc is a Maryland corporation incorporated on March 27, 2007. It is a holding company that through its wholly-owned subsidiary Shaanxi Biostar Biotech, Ltd. and its variable interest entities Shaanxi Aoxing Pharmaceutical Co., Ltd., and Shaanxi Weinan Aoxing Pharmaceuticals, LLC develops, manufactures and markets pharmaceutical products for a variety of diseases and conditions in the Peoples Republic of China. Its popular product is Xin Ao Xing Oleanolic Acid Capsule, an over-the- counter (OTC) medicine for chronic hepatitis B. Its product line also includes five other OTC products, ten prescription-based pharmaceuticals, six nutriceuticals or health products and one medical device. The Company's products are derived from medicinal herbs that are either grown at its own facility or purchased from its suppliers. It has currently eight products under development to complement its existing product line. It has adopted international manufacturing standards and currently holds one patent, with two additional patents pending approval. The Company's products are currently being sold in over 25 provinces in the PRC through 25 distributors and an established network of more than 400 dedicated sales people. The Company's competitors includes, Wulanhaote Zhong Meng pharmaceutical Co., Ltd., Yang Ling Mai Di Sen Pharmaceutical Co., Ltd, Jiang Xi Ren He Pharmaceuticals, Inc; Hainan Asia Pharmaceuticals, Inc; Nan Yong An Pharmaceuticals, Inc; Hai Nan Min Hai Pharmaceuticals, Ltd; Shandong Bai Cao Pharmaceuticals, Ltd; Chang Chun Ren Min Pharmaceuticals, Ltd; Yun Nan Yu Xi City Wei He Pharmaceutical, Ltd; Shandong Phoenix Pharmaceuticals, Ltd; Wulanhaote Zhong Meng Pharmaceutical Co., Ltd; Yang Ling Mai Di Sen Pharmaceutical Co., Ltd; and other traditional Chinese medicine suppliers. The Company' operations and facilities are subject to environmental laws and regulations stipulated by the national and the local environment protection bureaus in the PRC.
» More Articles for BSPM

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: ANADIGICS Inc., Biostar Pharmaceuticals Inc., Astrotech Corp. May 30 2011 

More From Other Websites
Nasdaq stocks posting largest volume increases Dec 24 2014
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Dec 05 2014
BIOSTAR PHARMACEUTICALS, INC. Financials Nov 22 2014
Biostar Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results Nov 15 2014
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Nov 14 2014
Biostar Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results Nov 14 2014
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant,... Oct 23 2014
Biostar Pharmaceuticals, Inc. Files a PRC Patent Application for Oleanolic Acid Injection, its New... Sep 18 2014
Biostar Pharmaceuticals Inc. Engaged Chief Scientist Professor Xiaohui Zheng To Preside Over The... Aug 27 2014
Sinopharm, Biostar, Lilly Rise on Medical Modernization in China Aug 18 2014
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Aug 14 2014
Biostar Pharmaceuticals, Inc. Announces Second Quarter 2014 Financial Results Aug 14 2014
Biostar Pharmaceuticals Inc. Established a Sales and Marketing Task Team to Promote Sales to... Aug 04 2014
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 15 2014
Biostar Pharmaceuticals, Inc. Announces First Quarter 2014 Financial Results May 15 2014
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Mar 31 2014
Biostar Pharmaceuticals, Inc. Announces Full Year 2013 Financial Results Mar 31 2014
Biostar Announces Execution of Agreement for $4.1 Million Registered Direct Offering of Shares of... Mar 10 2014
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Mar 10 2014
Biostar Announces Execution of Agreement for $4.1 Million Registered Direct Offering of Shares of... Mar 10 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK